logo

OTLK

Outlook Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.48 / 10
Netural

Financial analysis yields a mixed rating (5.5/10). Key positives include a healthy inventory turnover ratio (0.8126) and a strong interest-coverage ratio (48.59%), suggesting solid liquidity and debt management. However, the stock's revenue, profit, and asset multiples relative to market value show negative or neutral trends, tempering the overall fundamental outlook. Historical back-tests indicate modest one-month returns with varying confidence levels, reinforcing the need for caution.

Fundamental(5.48)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value-1.66
Score3/3
Weight21.03%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value54.19
Score3/3
Weight1.36%
1M Return0.88%
Inventory turnover ratio
Value0.81
Score2/3
Weight-1.75%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight16.88%
1M Return8.99%
PB-ROE
Value0.83
Score2/3
Weight22.60%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value48.59
Score2/3
Weight-1.82%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value74.94
Score2/3
Weight0.15%
1M Return0.10%
Asset-MV
Value-0.51
Score3/3
Weight26.78%
1M Return11.94%
Net profit / Total profit (%)
Value97.57
Score2/3
Weight-1.44%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight16.20%
1M Return8.80%
Is OTLK undervalued or overvalued?
  • OTLK scores 5.48/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -4416.22% net margin, -0.51 P/E ratio, -0.98 P/B ratio, and 55.91% earnings growth, these metrics solidify its Netural investment rating.